Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818040 or phil@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
phil@zenopa.com
+44 1494 818040

Testimonials
One of the frustrations from the candidate side is when communication stops and you do not know whether the role is still live or not.
Tony, 2011

Bayer HealthCare announces positive Nexavar thyroid cancer data

3 January 2013 11:28 in Pharmaceutical Company Product News


Bayer HealthCare and partner Onyx Pharmaceuticals have unveiled new clinical trial data showing the potential of Nexavar tablets to treat a certain form of cancer.

Results from the phase III Decision study demonstrated that Nexavar delivered progression-free survival benefits among patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.

The safety and tolerability profiles of the drug were also shown to be positive, suggesting Nexavar could be an effective therapy for a condition for which there are currently limited options available.

Bayer plans to submit the Decision data to support marketing authorisation applications for Nexavar in the treatment of RAI-refractory differentiated thyroid cancer.

Dr Dimitris Voliotis, vice-president for global clinical oncology development at Bayer HealthCare, said: "We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients."

This comes after the firm submitted radium-223 dichloride for European approval in the treatment of castration-resistant prostate cancer last month.ADNFCR-8000103-ID-801515813-ADNFCR

Other news stories from 03/01/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd